Ofra Kalter-Leibovici, MD

Articles by Ofra Kalter-Leibovici, MD

Disease Management Programs: Barriers and Benefits

ByRacheli Magnezi, MBA, PhD,Galit Kaufman, RN, MA,Arnona Ziv, MBA,Ofra Kalter-Leibovici, MD,Haim Reuveni, MD

April 16th 2013

Perceived barriers and benefits to implementing disease management programs among Israeli healthcare leaders could assist other countries faced with increasing numbers of chronically ill patients.

Latest Updated Articles

Disease Management Programs: Barriers and Benefits
April 16th 2013

Ofra Kalter-Leibovici, MD

Articles by Ofra Kalter-Leibovici, MD

Disease Management Programs: Barriers and Benefits

Latest Updated Articles

Trending on AJMC

FDA Panel Backs 6 Peptides for Compounding

FDA Approves Lutetium Lu 177 for Earlier-Stage Prostate Cancer

Atacicept Becomes First BAFF/APRIL Inhibitor Approved for IgA Nephropathy: Richard Lafayette, MD

From CAR T-Cell Therapy to ADCs: Tackling Oncology Access Gaps

Boston Panel Confronts Access and Coordination Gaps in Obesity Care

A Look at PBM Reform and Transparency: Payer, Provider and Patient Impact

Ofra Kalter-Leibovici, MD

Articles by Ofra Kalter-Leibovici, MD

Disease Management Programs: Barriers and Benefits

Latest Updated Articles

Trending on AJMC

FDA Panel Backs 6 Peptides for Compounding

FDA Approves Lutetium Lu 177 for Earlier-Stage Prostate Cancer

Atacicept Becomes First BAFF/APRIL Inhibitor Approved for IgA Nephropathy: Richard Lafayette, MD

From CAR T-Cell Therapy to ADCs: Tackling Oncology Access Gaps

Boston Panel Confronts Access and Coordination Gaps in Obesity Care